Skip to main content

Entrada Therapeutics, Inc. (TRDA)

Sector
Biotechnology
Last price
$4.96
As of

Kresmion compiles this page from TRDA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Entrada Therapeutics, Inc. (TRDA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.

As of . Source: SEC EDGAR filings for TRDA. Method and limitations.

COMPANY DOSSIER

See the full TRDA dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for TRDA on one page. Preview it with sample data, then open it live with a free account.

Preview the TRDA dossier

Active events for TRDA

FREE, NO ACCOUNT

Every event on TRDA, as it fires

You are seeing 5 of 9 events recorded on TRDA since 2026-05-24.

The five above landed across 4 days. The other 4 were recorded on 1 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

TRDA positions held by the managers we follow (2026Q3)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 29384C108 · 2026Q3$1.3M0.00%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, TRDA

Going concern statement

TRDA's 10-Q filed Nov 5, 2026 states:

We have identified conditions that raise substantial doubt about our ability to continue as a going concern.

Read the 10-Q on SEC EDGAR Every company with a going concern statement

More data on TRDA

TRDA against its peers

TRDA's operating margin of -621.1% ranks in the 37th percentile of 14 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricTRDAPeer medianPercentilen
Revenue FY25.4M USD12.0M USD7714
Revenue YoYn/a-16.0%n/a6
Gross marginn/a82.8%n/a7
Operating margin-621.1%-262.4%3714
Net margin-565.5%-288.3%4115
Return on equity-47.0%-56.3%5721
1 year-45.5%-7.1%2323

Peers (23): PRQR, CGEN, ARTV, PALI, NGEN, RNAC, PYXS, ACIU, KRRO, IKT, MDWD, PROK, GLSI, WHWK, SLGL, KROS, ANIK, ELDN, ANTX, ACOG, LCTX, IFRX, BBOT. Left out: HSTC (period gap), DRUG (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TRDA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in TRDA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TRDA in the last 180 days.

Upstream: SEC EDGAR filings for TRDA

Kresmion, "Entrada Therapeutics, Inc. (TRDA) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/TRDA. Upstream data: SEC EDGAR filings for TRDA.

Link to this data (HTML):

<a href="https://kresmion.com/research/TRDA">Entrada Therapeutics, Inc. (TRDA) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow TRDA on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TRDA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the TRDA dossier
Share

The TRDA intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.